Edgewise Therapeutics, Inc. EWTX
Our mission is to discover new medicines that improve the lives of people facing serious muscle disease.
At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combined our foundational expertise in muscle biology and small molecule engineering to build our proprietary, muscle focused drug discovery platform. Our platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. We have developed and characterized a library of novel sarcomere modulators exhibiting a broad range of pharmacological and pharmacokinetic (PK) properties regulating disease-related muscle biology. Based on the results of our drug discovery platform, we are advancing multiple clinical-stage programs in muscular dystrophies and severe cardiac diseases, as well as a number of preclinical programs.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $151.4M | $127.0M | $90.9M | $54.0M | $32.2M | $15.0M | — |
| SG&A | $40.0M | $31.9M | $23.5M | $17.6M | $11.0M | $2.2M | — |
| Total operating expenses | $191.4M | $158.8M | $114.4M | $71.7M | $43.2M | $17.2M | — |
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M | -$17.2M | — |
| Pre-tax income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M | — | — |
| Income tax | $4.0K | $3.0K | $4.0K | $0 | $0 | — | — |
| Net income | -$167.8K | -$133.8K | -$100.2K | -$67.6M | -$42.8M | -$17.1M | — |
| EPS, basic | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 | -23.17 | — |
| EPS, diluted | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 | -23.17 | — |
| Shares, diluted (wtd. avg.) | 102.9M | 92.4M | 63.7M | 53.6M | 37.5M | 739,004 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.1M | $41.7M | $86.1M | $22.0M | $15.6M | $104.9M | $23.7M |
| Total current assets | $543.4M | $475.5M | $327.0M | $357.0M | $283.8M | $129.6M | — |
| Property, plant and equipment | $7.8M | $9.5M | $10.4M | $8.5M | $912.0K | $516.0K | — |
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M | $131.1M | — |
| Accounts payable | $6.0M | $5.6M | $4.0M | $6.1M | $3.8M | $1.6M | — |
| Total current liabilities | $27.4M | $23.9M | $16.8M | $16.6M | $10.5M | $4.3M | — |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M | $4.3M | — |
| Retained earnings | -$546.4M | -$378.6M | -$244.8M | -$144.6M | -$77.0M | -$34.1M | — |
| Total equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M | -$33.4M | -$16.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M | -$14.6M | — |
| Depreciation and amortisation | $2.1M | $2.1M | $1.6M | $368.0K | $272.0K | $185.0K | — |
| Stock-based compensation | $34.8M | $24.7M | $17.6M | $10.9M | $4.4M | $354.0K | — |
| Capital expenditure | $256.0K | $1.3M | $5.7M | $5.5M | $668.0K | $203.0K | — |
| Investing cash flow | -$32.8M | -$184.7M | $102.9M | -$70.6M | -$242.2M | -$24.4M | — |
| Financing cash flow | $196.1M | $249.3M | $53.2M | $129.6M | $186.4M | $120.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-047688.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$17.1M | -$42.8M | -$67.6M | -$100.2K | -$133.8K | -$167.8K |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |